Evidence map›Paper›PMID 32862776›Full record

ReviewMolecular imaging

Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy.

Liqin Zhu, Zhikai Ding, Xingliang Li, Hongyuan Wei, Yue Chen

Open access · goldAbstract readReview
In one paragraph

Review in Molecular imaging. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Preclinical evaluation of a dual-receptor targeted tracer [European journal of nuclear medicine and molecular imaging · 2023
    Article
  7. Article
  8. Review
  9. Scandium-44: Diagnostic Feasibility in Tumor-Related Angiogenesis.International journal of molecular sciences · 2023
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Synthesis ofPharmaceutics · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Liqin ZhuDepartment of Nuclear Medicine, 556508The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, People's Republic of China.ORCID 0000-0003-0844-985X
Zhikai DingDepartment of Nuclear Medicine, 556508The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
Xingliang LiInstitute of Nuclear Physics and Chemistry, China Academy of Engineering Physics, Mianyang, Sichuan, People's Republic of China.
Hongyuan WeiDepartment of Nuclear Medicine, 556508The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
Yue ChenDepartment of Nuclear Medicine, 556508The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
Affiliated Hospital of Southwest Medical University · CNChina Academy of Engineering Physics · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asn-Gly-Arg (NGR) motifs have vasculature-homing properties via interactions with the aminopeptidase N (CD13) expressed on tumor neovasculature. Numerous NGR peptides with different molecular scaffolds have been exploited for targeted delivery of different compounds for imaging and therapy. When conjugated with NGR, complexes recognize the CD13 receptor expressed on the tumor vasculature, which improves the specificity to tumor and avoids systematic toxic reactions. Both preclinical and clinical studies performed with these products suggest that NGR-mediated vascular targeting is an effective strategy for delivering bioactive amounts of cytokines to tumor endothelial cells. For molecular imaging, radiolabeled peptides have been the most successful approach and have been translated into clinic. This review describes current data on radiolabeled tumor vasculature-homing NGR peptides for imaging and therapy.

Indexed as

Biomedical ResearchAnimalsDrug Delivery SystemsHumansMolecular ImagingNeoplasmsOligopeptidesRadiopharmaceuticalsNGR peptideOligopeptidesRadiopharmaceuticalsimagingNGRradiolabeledtherapytumor

Identifiers

PMID32862776
PMCPMC7466889
OpenAlexW3082753271

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.